86 results
8-K
EX-99.1
CPRX
Catalyst Pharmaceuticals Inc
27 Oct 23
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals
4:30pm
Dystrophy and potentially other chronic inflammatory diseases. The approval of AGAMREE underscores the potential of reshaping the DMD treatment paradigm
8-K
EX-99.1
CPRX
Catalyst Pharmaceuticals Inc
22 Mar 21
Catalyst Pharmaceuticals Announces $40 Million Share Repurchase Program
8:35am
therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that its Board of Directors has authorized … on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including
8-K
EX-99.1
CPRX
Catalyst Pharmaceuticals Inc
16 Mar 21
Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update
8:11am
and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today reported financial results … innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS
8-K
EX-99.1
6f1fp287 ud0
6 Jan 21
Catalyst Pharmaceuticals Announces Strategic Plan for Product Portfolio Expansion for Long-Term Success and Provides Corporate Update
4:28pm
8-K
EX-99.1
v7yv crkphfi
10 Nov 20
Catalyst Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update
12:00am
8-K
EX-99.1
2uj8brderqlk4h
19 Oct 20
Catalyst Pharmaceuticals Announces Filing of Patent Infringement Actions Against Jacobus Pharmaceuticals and PantherRx
8:04am
8-K
EX-99.1
jr3lp1shtrfwhj
6 Oct 20
Other Events
5:26pm
8-K
EX-99.1
zowz9k65
30 Sep 20
Catalyst Pharmaceuticals Announces Ruling on Lawsuit against the FDA and Intent to Appeal
12:00am
8-K
EX-99.1
pbsb2
26 Aug 20
Other Events
5:00pm
8-K
EX-99.1
bah0 f6tx
20 Aug 20
Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce Agreement to Make Firdapse® (amifampridine phosphate) Available to LEMS Patients in Canada
5:15pm
8-K
EX-99.1
i0pl1rrb9af add
11 Aug 20
Catalyst Pharmaceuticals Announces Notice of Allowance of a U.S. Patent Application for “Methods of Administering 3,4
4:46pm
8-K
EX-99.1
qawlx lt5
10 Aug 20
Catalyst Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update
5:17pm
8-K
EX-99.1
wh8e ltgv
6 Aug 20
Catalyst Pharmaceuticals’ Firdapse® (amifampridine phosphate) Receives
4:31pm
8-K
EX-99.2
lpb8537ini r4
3 Aug 20
Catalyst Pharmaceuticals Announces Change to a Virtual Meeting Format for the 2020 Annual Meeting of Stockholders
5:05pm
8-K
EX-99.1
0pf8uz7 pe
3 Aug 20
Catalyst Pharmaceuticals Announces Change to a Virtual Meeting Format for the 2020 Annual Meeting of Stockholders
5:05pm